<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02637453</url>
  </required_header>
  <id_info>
    <org_study_id>ShanghaiXinhua-Af</org_study_id>
    <nct_id>NCT02637453</nct_id>
  </id_info>
  <brief_title>Addition of Six Short Lines on Pulmonary Vein Isolation</brief_title>
  <official_title>Addition of Six Short Ablation Lines on Pulmonary Vein Isolation Circumferences Reduces Recurrence Rate of Paroxysmal Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xuzhou Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai East Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We randomly assigned 390 patients with symptomatic, paroxysmal AF to undergo catheter&#xD;
      ablation with PVI (PVI group) alone or combined with 6 additional ablation lines extended&#xD;
      outside the PVI circumferences at 1, 3 and 6 o'clock of left PV and 6, 9 and 11 o'clock of&#xD;
      right PV (PVI+6L group). Patients received monthly 12-lead electrocardiogram, 24-hour Holter&#xD;
      at 3, 6 and 9 months and 14-days continuous monitoring at 12 months to detect atrial&#xD;
      tachyarrhythmia. The follow-up period was 12 months. The primary end point was freedom from&#xD;
      AF recurrence between 91 and 365 days after catheter ablation. The secondary end points&#xD;
      included the AF burden, procedural parameters, and complications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We randomly assigned 390 patients with symptomatic, paroxysmal AF to undergo catheter&#xD;
      ablation with PVI (PVI group) alone or combined with 6 additional ablation lines extended&#xD;
      outside the PVI circumferences at 1, 3 and 6 o'clock of left PV and 6, 9 and 11 o'clock of&#xD;
      right PV (PVI+6L group). Patients received monthly 12-lead electrocardiogram, 24-hour Holter&#xD;
      at 3, 6 and 9 months and 14-days continuous monitoring at 12 months to detect atrial&#xD;
      tachyarrhythmia. The follow-up period was 12 months. The primary end point was freedom from&#xD;
      AF recurrence between 91 and 365 days after catheter ablation. The secondary end points&#xD;
      included the AF burden, procedural parameters, and complications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 4, 2017</start_date>
  <completion_date type="Actual">January 10, 2021</completion_date>
  <primary_completion_date type="Actual">January 10, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from AF recurrence between 91 and 365 days</measure>
    <time_frame>91 to 365 days</time_frame>
    <description>AF recurrence was defined by AF (including atrial flutter or atrial tachycardia) of 30 seconds or more captured by ECG monitoring or any clinical presentation with AF outside the 90-day blanking period (between 91 and 365 days). Cardioversion, or use of class I or III antiarrhythmic drugs outside blanking period was also considered as AF recurrence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AF burden</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of time in AF, atrial flutter or atrial tachycardia on 14-days continuous monitoring at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural time</measure>
    <time_frame>Within procedure</time_frame>
    <description>Total procedural time from femoral vein puncture to decannulation (skin-to-skin time)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopy time</measure>
    <time_frame>Within procedure</time_frame>
    <description>Time of patients' exposure to the real-time X-ray imaging during the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ablation time</measure>
    <time_frame>Within procedure</time_frame>
    <description>Radiofrequency delivery time during the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early onset complications</measure>
    <time_frame>Within 30 days</time_frame>
    <description>Complications within 30 days post-ablation, including death, myocardial infarction, diaphragmatic paralysis, stroke or transient ischemic attack, systemic embolism, pericardial effusion or tamponade requiring drainage, heart block, pericarditis, and vascular access complications requiring intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late onset complications</measure>
    <time_frame>within 12 months</time_frame>
    <description>Complications detected any time during the follow-up, including severe pulmonary vein stenosis (&gt;70%), and atrioesophageal fistula.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">390</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>PVI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pulmonary vein isolation (PVI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PVI+6L</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PVI plus 6 additional lines at 1, 3 and 6 o'clock (from internal view) of left PV and 6, 9 and 11 o'clock of right PV</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PVI</intervention_name>
    <description>Pulmonary vein isolation</description>
    <arm_group_label>PVI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CPVI+6L</intervention_name>
    <description>After PVI, 6 ablation lines were added with an extension from pulmonary vein ostium at 1, 3 and 6 o'clock (from internal view) of left PV and 6, 9 and 11 o'clock of right PV</description>
    <arm_group_label>PVI+6L</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          1. Patients between the ages of 18 and 80 years undergoing their first ablation of atrial&#xD;
             fibrillation.&#xD;
&#xD;
          2. Diagnosed with symptomatic paroxysmal atrial fibrillation, defined as an documented&#xD;
             episode of atrial fibrillation that lasts more than 30 seconds and terminates in less&#xD;
             than 7 days.&#xD;
&#xD;
          3. Resistant or intolerant to at least one class I, II, or III antiarrhythmic drugs.&#xD;
&#xD;
          4. Patients deemed candidates for radiofrequency ablation of atrial fibrillation.&#xD;
&#xD;
          5. Able and willing to comply with pre-, post-, and follow-up requirements.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Left atrial thrombus by pre-procedural imaging.&#xD;
&#xD;
          2. Uncontrolled heart failure: New York Heart Association Class III or IV, or left&#xD;
             ventricular ejection fraction&lt; 40%&#xD;
&#xD;
          3. Myocardial infarction, unstable angina, coronary stenting within the previous 90 days.&#xD;
&#xD;
          4. Stroke or any thrombo-embolic events within the previous 90 days.&#xD;
&#xD;
          5. Expecting cardiac transplantation or other cardiac surgery within 180 days.&#xD;
&#xD;
          6. History of catheter ablation of atrial fibrillation, atrial flutter or atrial&#xD;
             tachycardia.&#xD;
&#xD;
          7. History of blood clotting or bleeding abnormalities.&#xD;
&#xD;
          8. Contraindication to anticoagulation.&#xD;
&#xD;
          9. History of cardiac surgery.&#xD;
&#xD;
         10. Uncontrolled maligment tumor.&#xD;
&#xD;
         11. Patients in dialysis or creatinine &gt; 221 μmol/L.&#xD;
&#xD;
         12. Patients with alanine aminotransferase &gt; 150 U/L or aspartate aminotransferase &gt; 76&#xD;
             U/L&#xD;
&#xD;
         13. Acute illness or active infection at time of index procedure or leukocytosis for which&#xD;
             antibiotics have been or will be prescribed.&#xD;
&#xD;
         14. Life expectancy less than 1 year.&#xD;
&#xD;
         15. Women who are pregnant or who plan to become pregnant during the study.&#xD;
&#xD;
         16. Other significant congenital anomaly or medical problem that in the opinion of the&#xD;
             investigator would preclude enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi-Gang Li, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, Xinhua Hospital, Shanghai Jiaotong University School of Medicne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xinhua Hospital, Shanghai Jiao Tong University School of Medicne</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Steinberg BA, Beckley PD, Deering TF, Clark CL, Amin AN, Bauer KA, Cryer B, Mansour M, Scheiman JM, Zenati MA, Newby LK, Peacock WF, Bhatt DL; Society of Cardiovascular Patient Care. Evaluation and management of the atrial fibrillation patient: a report from the Society of Cardiovascular Patient Care. Crit Pathw Cardiol. 2013 Sep;12(3):107-15. doi: 10.1097/HPC.0b013e31829834ed.</citation>
    <PMID>23892939</PMID>
  </reference>
  <reference>
    <citation>Haïssaguerre M, Jaïs P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue S, Le Mouroux A, Le Métayer P, Clémenty J. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998 Sep 3;339(10):659-66.</citation>
    <PMID>9725923</PMID>
  </reference>
  <reference>
    <citation>Zhang S. Atrial fibrillation in mainland China: epidemiology and current management. Heart. 2009 Jul;95(13):1052-5. doi: 10.1136/hrt.2008.146589. Epub 2009 Mar 23. Review.</citation>
    <PMID>19318342</PMID>
  </reference>
  <reference>
    <citation>Weerasooriya R, Khairy P, Litalien J, Macle L, Hocini M, Sacher F, Lellouche N, Knecht S, Wright M, Nault I, Miyazaki S, Scavee C, Clementy J, Haissaguerre M, Jais P. Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up? J Am Coll Cardiol. 2011 Jan 11;57(2):160-6. doi: 10.1016/j.jacc.2010.05.061.</citation>
    <PMID>21211687</PMID>
  </reference>
  <reference>
    <citation>Cheema A, Vasamreddy CR, Dalal D, Marine JE, Dong J, Henrikson CA, Spragg D, Cheng A, Nazarian S, Sinha S, Halperin H, Berger R, Calkins H. Long-term single procedure efficacy of catheter ablation of atrial fibrillation. J Interv Card Electrophysiol. 2006 Apr;15(3):145-55. Epub 2006 Aug 5.</citation>
    <PMID>17019636</PMID>
  </reference>
  <reference>
    <citation>Ouyang F, Tilz R, Chun J, Schmidt B, Wissner E, Zerm T, Neven K, Köktürk B, Konstantinidou M, Metzner A, Fuernkranz A, Kuck KH. Long-term results of catheter ablation in paroxysmal atrial fibrillation: lessons from a 5-year follow-up. Circulation. 2010 Dec 7;122(23):2368-77. doi: 10.1161/CIRCULATIONAHA.110.946806. Epub 2010 Nov 22.</citation>
    <PMID>21098450</PMID>
  </reference>
  <reference>
    <citation>Calò L, Rebecchi M, Sciarra L, De Luca L, Fagagnini A, Zuccaro LM, Pitrone P, Dottori S, Porfirio M, de Ruvo E, Lioy E. Catheter ablation of right atrial ganglionated plexi in patients with vagal paroxysmal atrial fibrillation. Circ Arrhythm Electrophysiol. 2012 Feb;5(1):22-31. doi: 10.1161/CIRCEP.111.964262. Epub 2011 Dec 6.</citation>
    <PMID>22147839</PMID>
  </reference>
  <reference>
    <citation>Katritsis DG, Pokushalov E, Romanov A, Giazitzoglou E, Siontis GC, Po SS, Camm AJ, Ioannidis JP. Autonomic denervation added to pulmonary vein isolation for paroxysmal atrial fibrillation: a randomized clinical trial. J Am Coll Cardiol. 2013 Dec 17;62(24):2318-25. doi: 10.1016/j.jacc.2013.06.053. Epub 2013 Aug 21.</citation>
    <PMID>23973694</PMID>
  </reference>
  <reference>
    <citation>Noheria A, Kumar A, Wylie JV Jr, Josephson ME. Catheter ablation vs antiarrhythmic drug therapy for atrial fibrillation: a systematic review. Arch Intern Med. 2008 Mar 24;168(6):581-6. doi: 10.1001/archinte.168.6.581. Review.</citation>
    <PMID>18362249</PMID>
  </reference>
  <reference>
    <citation>Stabile G, Bertaglia E, Senatore G, De Simone A, Zoppo F, Donnici G, Turco P, Pascotto P, Fazzari M, Vitale DF. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). Eur Heart J. 2006 Jan;27(2):216-21. Epub 2005 Oct 7.</citation>
    <PMID>16214831</PMID>
  </reference>
  <reference>
    <citation>Wilber DJ, Pappone C, Neuzil P, De Paola A, Marchlinski F, Natale A, Macle L, Daoud EG, Calkins H, Hall B, Reddy V, Augello G, Reynolds MR, Vinekar C, Liu CY, Berry SM, Berry DA; ThermoCool AF Trial Investigators. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA. 2010 Jan 27;303(4):333-40. doi: 10.1001/jama.2009.2029.</citation>
    <PMID>20103757</PMID>
  </reference>
  <reference>
    <citation>Reddy VY, Dukkipati SR, Neuzil P, Natale A, Albenque JP, Kautzner J, Shah D, Michaud G, Wharton M, Harari D, Mahapatra S, Lambert H, Mansour M. Randomized, Controlled Trial of the Safety and Effectiveness of a Contact Force-Sensing Irrigated Catheter for Ablation of Paroxysmal Atrial Fibrillation: Results of the TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation (TOCCASTAR) Study. Circulation. 2015 Sep 8;132(10):907-15. doi: 10.1161/CIRCULATIONAHA.114.014092. Epub 2015 Aug 10.</citation>
    <PMID>26260733</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 16, 2015</study_first_submitted>
  <study_first_submitted_qc>December 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2015</study_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Yi-Gang Li</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Paroxysmal Atrial Fibrillation; Ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

